barbara marston, m.d. care and treatment team, gap, atlanta
DESCRIPTION
Why we shouldn’t (yet) move to TDF/FTC as the primary first line regimen for PEPFAR-supported programs. Barbara Marston, M.D. Care and Treatment Team, GAP, Atlanta. Considerations in choice of first line regimen. Effectiveness of TDF. Potent, well-tolerated, once daily drug - PowerPoint PPT PresentationTRANSCRIPT
Why we shouldn’t (yet) move to TDF/FTC as the primary first line regimen for PEPFAR-supported
programs
Barbara Marston, M.D.
Care and Treatment Team, GAP, Atlanta
Considerations in choice of first line regimen
TDF d4T
Effectiveness
Side Effects
Impact on Resistance
Drug interactions
Impact on co-infections
Impact on adherence (# of pills, # of doses, tolerability)
Supply chain (FDCs, shelf life, storage conditions)
Costs
Effectiveness of TDF
• Potent, well-tolerated, once daily drug• In once daily regimens, ~superior to d4t in twice a day
regimens and superior to ZDV given in twice a day regimens
• Not clear how this might translate in Africa– Concern with routine EFV in women of child bearing age – Not certain that effectiveness will hold up with NVP
• Discomfort with NVP in once daily regimen• Giving NVP twice daily might balance some of the TDF advantage
– FDCs with NVP not yet available – Effectiveness of TDF in these studies might have been in part
related to daily dosing
Advantages of FDCs
• Contribute to adherence
• Reduce risk of taking partial regimens, stock outs
• Contribute to simplicity with respect to forecasting/procurement/distribution
Costs
• Consider costs in general, not just for PEPFAR
• Consider not just the cost of this action but the costs in the context of other things we’re not doing
• Many ways to consider costs
• Can we reduce costs?
Costs
• Important to consider costs in general, not just for PEPFAR – An isolated decision to use TDF in PEPFAR
programs would be “problematic” – Important that choice of first line regimens not
be a PEPFAR decision, but a series of national decisions
Costs
• Need to consider not just the cost of this action (“should we do it”) but the costs in the context of other things we’re not doing (“should we do this, or should we spend additional money on prevention, cotrimoxazole, immunizations, education”).
• Shameless plug for CTX
(cost savings of $2.50 to cost of $6 per DALY
vs. ~$600 per DALY for ART)
Costs
• There is potential to further reduce costs, but TDF costs are likely to remain higher than stavudine costs– 5x the raw materials– 6-7 step production vs. 1 step
• Can consider costs in many ways (costs of TDF only, costs of regimens with or without TDF, costs of health care with or without TDF).
• The question is not whether TDF is superior to d4T for 1 person—the question is “What is the best thing to do with the money?”– Drugs only (adding ARVs for an additional person) 2:1– Add people on treatment 5:4
Or
Or
Or
5:4 may look like a modest difference, but…
050,000
100,000150,000200,000250,000300,000350,000400,000450,000500,000
Nigeria
Tanzan
ia
Ethiopia
Moz
ambig
ueHaiti
South
Africa
Cote d
'Ivoir
e
Vietn
am
Kenya
Zambia
Uganda
Guyana
Rwanda
Namibi
a
Botswan
a
0102030405060708090100
Series2 Series1 Series3
Measuring Progress in Treatment Measuring Progress in Treatment 07 SAPR Data07 SAPR Data
Total in need of ARTTotal currently receiving ARTPercentage of coverage
550,000 1000,000
Moz
ambiq
ue
There is an enormous unmet need
• Terrific progress toward targets, but…
• We are no where near universal access– ~7M currently in immediate need of ART – ~2M currently accessing treatment (probably
includes some people not in the denominator)– Even if we stopped HIV in its tracks, need will
grow astronomically (see Jeff’s slide)– We haven’t stopped HIV in its tracks
Barb’s thoughts
• No need for this to be an “all-or-none decision”• Reasonable to consider TDF regimens for those
with hepatitis or SEs from stavudine• I would shy away from use of “PEPFAR-
Supported” as the criterion for determining drug choice
• Need to evaluate durability of viral suppression with TDF in Africa, develop NVP- based FDCs
• Think hard about priorities and the people you can’t see
• Maybe we just need more money.
Thank You
ARVs
OI drugs
Personnel, infrastructure
Non-
ARV
Costs of providing HIV care to a population
ARVs
OI drugs
Personnel, infrastructure
Non-
ARV
Add an expensive ARV
ARVs
OI drugs
Personnel, infrastructure
Non-
ARV
Add a less expensive ARV
ARVs
OI drugs
Personnel, infrastructure
Non-
ARV
Add people without ARVs
ARVs
OI drugs
Personnel, infrastructure
Non-
ARV
Add people with less expensive ARVs
ARVs
OI drugs
Personnel, infrastructure
Non-
ARV
Add people with more expensive ARVs